Semaglutide Receives Votes in Favor of Approval From the FDA

October 18, 2017. An advisory committee of the US Food and Drug Administration (FDA) voted to recommend approval of Novo Nordisk’s semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), to improve glycemic control in adults with type 2 diabetes (T2D). The decision was based on efficacy and safety data from 8 clinical trials, which involved more than 8,000 adults with T2D. You can read more about the vote here and can review the full semaglutide briefing document here.